Acute myeloid leukemia (AML) with minimal differentiation was usually referred to as acute undifferentiated leukemia in the past. With the help of immunophenotyping, this subtype of leukemia was shown to express myeloid antigens on the blasts and was designated AML-M0 by FAB Cooperative Study Group in 1991. Among the 423 consecutive newly diagnosed de novo AML at our institution, 12 (2.8%) were of M0 subtype. The proportion of M0 in AML was higher in children than in adults (8.2% vs 1.7%). Four other M0 patients referred from outside hospitals for immunophenotyping were also included in this study. There were two peaks in age distribution of these 16 patients: less than 3 years and between 51 and 70 years, respectively. Organomegaly was more common in patients with AML-M0 than in those with other subtypes (56.3% vs 29.2%, P = 0.025). The former patients had higher incidences of CD7 and CD34 expression on the leukemic cells than the latter ones (50% vs 16.9%, P = 0.003 and 69.2% vs 37.9%, P = 0.019, respectively). The patients with AML-M0 showed more frequent clonal chromosomal abnormalities in the leukemic cells than other AML patients (83.3% vs 53.9%, P = 0.039); the same is also true for complex cytogenetic aberrations (50% vs 11.4%, P = 0.004). Adults with AML-M0 showed a lower complete remission (CR) rate and significantly poorer survival than those with non M0-AML. However there was no significant difference in outcome between the two groups of pediatric patients. In conclusion, AML-M0 is a unique subtype of leukemia that has distinct age distribution and shows different clinical and biological characteristics from other AML. Adult patients have poor prognosis. Whether pediatric patients had better outcome than adults needs to be clarified in further studies.
Introduction
Minimally differentiated acute myeloid leukemia (AML) was recognized as a distinct entity by Lee et al . 1 This subtype of leukemia was mostly referred to as acute undifferentiated leukemia (AUL) in the past for undifferentiated morphological and cytochemical features of the leukemic cells, 1,2 which made correct identification of cell lineages of the cells difficult. By immunophenotypic, ultrastructural and molecular studies later on, it was clarified that leukemic cells from some AUL had commitment to primitive myeloid differentiation. [3] [4] [5] Recently, the French-American-British (FAB) Cooperative Group proposed the diagnostic criteria for this form of leukemia, designated AML-M0, with minimal myeloid differentiation: 3 negative myeloperoxidase (MPO), expression of myeloid antigens and negative B and T lineage markers with exceptions to CD7 and CD4. A low remission rate and poor prognosis after conventional chemotherapy in adult patients with AML-M0 has been reported, possibly because of the frequent occurrence of unfavorable cytogenetic abnormalities, expression of immature surface antigens and multidrug resistance-associated membrane protein. [6] [7] [8] [9] [10] [11] So far, no comprehensive studies on pediatric patients with AML-M0 have been reported and there have been very few data in the literature concerning age distribution of this subtype of leukemia. The clinical and biological differences between AML-M0 patients who are responsive to chemotherapy and those who are not are also not clear. Herein we analyze the characteristics of 16 patients, including adults and children, with de novo AML-M0. Our data indicate that there are two peaks in age distribution of AML-M0, one in children younger than 3 years and the other in adults between 51 and 70 years. Most adult patients were refractory to chemotherapy and had poor prognosis, but a trend of better response to treatment was noted in pediatric patients and some of them had long-term disease-free survival.
Materials and methods

Patients
From January 1986 to December 1997, 12 (2.8%) of the 423 consecutive patients with newly diagnosed de novo AML at our institution fit the diagnostic criteria of AML-M0, which is defined as the following: (1) less than 3% blast cells positive for MPO; (2) reactivity with CD33 and/or CD13 myeloid antigens; and (3) negativity for lymphoid-associated antigens with exception to CD7. 3 One patient with CD19 expression on leukemic cells was included because the blast cells were CD33 positive, had no rearrangements of immunoglobulin or T cell receptor ␤-chain gene, and showed MPO activity in a few cells (but Ͻ3%). Four other M0 patients referred from outside hospitals for immunophenotyping were also included. All these 16 patients were the subjects of this study. Pediatric patients were those less than 15-years-old. Adult patients were not treated on protocol but on conventional chemotherapy consisting of cytosine arabinoside and one of anthracyclines with or without other drugs, except one (case 16) who was treated with acute lymphoblastic leukemia (ALL)-directed chemotherapy initially (Table 1) . Pediatric patients were treated according to AML-901 protocol from Taiwan Pediatric Oncology Group (TPOG), described as following: (1 
Morphologic, cytochemical and immunochemical studies
The analyses of morphology, cytochemistry and immunochemistry of leukemic cells were performed as described previously. 12 Bone marrow (BM) smears were stained and evaluated according to the revised FAB criteria. 13 Cytochemical stains included MPO, combined chloroacetate esterase (CAE) and ␣-naphthyl-butyrate esterase (␣NBE) and periodic acidSchiff (PAS) reaction. The expression of surface antigens on leukemic cells was shown by an indirect immunoalkaline phosphatase method 12 using a panel of commercially available monoclonal antibodies to myeloid, erythroid, and platelet associated antigens, including CD13, CD33, CD15, CD14, CD11b, glycophorin-A and CD41, as well as lymphoid associated antigens, including CD2, CD3, CD5, CD7, CD10, CD19 and CD20. The expression of CD34 and HLA-DR was also examined. Leukemias were considered to be positive for a marker if more than 20% of the blasts were positive for that marker.
Cytogenetic analysis
Cytogenetic study was performed on BM cells after 1-3 days of unstimulated culture. Metaphase chromosomes were banded by the conventional trypsin-Giemsa banding technique and karyotyped according to the International System for Human Cytogenetic Nomenclature (ISCN).
14 Complex cytogenetic changes were defined by the presence of four or more chromosomal abnormalities in the same clone.
Southern blot analysis
Analysis of immunoglobulin (lg) heavy-chain and T cell receptor (TCR) ␤-chain gene rearrangements was performed according to the method described previously. 15 In brief, DNAs were extracted from cryopreserved BM or PB cells by cells lysis, proteinase K digestion, phenol/chloroform extraction and ethanol precipitation. Five micrograms of each DNA were digested with restriction enzyme BamHI and EcoRI in conditions recommended by the supplier (Boehringer, Mannheim, Germany), size fractionated by electrophoresis in a 0.7% agarose gel, and transferred to Hybond membrane (Amersham International, UK) with a standard Southern blot technique. DNA probes were labeled with 
Statistics
Differences of interval variables between M0 and non-M0 subtypes of AML were compared by independent samples t-test. Comparison of organomegaly and marker reactivity (considered as positive or negative) between the two groups of patients were estimated by Fisher's exact test. Difference of age distribution between the two groups of patients were estimated by Chi-square test. A P value of 0.05 or less was considered to be significant. The Kaplan-Meier survival curves were constructed for estimation of overall survival time, event-free survival time and continuous complete remission (CCR) duration. Overall survival time was calculated from the date of treatment to the date of death for any reasons. Data on the patients who were still alive at last follow-up or at the end of our study were censored. Event-free survival was the time from the date of treatment to the date of death or relapse, whichever occurred first. CCR duration was measured from achievement to CR until relapse. Patients who have received hematopoietic stem cell transplantation after remission are not censored. Those patients who did not receive conventional chemotherapy were excluded from the survival analysis. For comparison of survival and remission duration of two or more groups, the log-rank test was applied.
Results
Patients
The overall incidence of AML-M0 among de novo AML in our institution was 2.8% (12/423). 411 non-M0 patients were classified according to the FAB guidelines as follows: M1, 86 patients (20.3%); M2, 135 patients (31.9%); M3, 72 patients (17%); M4, 67 patients (15.8%); M5, 33 patients (7.8%); M6, 6 patients (1.4%); M7, 12 patients (2.8%). Pediatric patients had a higher incidence of AML-M0 (6/73, 8.2%) than adults (6/350, 1.7%). Four AML-M0 patients referred from outside hospitals for immunophenotyping were included for analyses of clinical and biological characteristics of this disease entity. The main features of these 16 AML-M0 patients are shown in Tables 1 and 2 . There were five males and 11 females. The Table 2 Hematologic characters and complete karyotypes at diagnosis in 16 patients of AML-M0 ages ranged from 1 month to 68 years with two peaks: less than 3 years (seven patients, 44%) and between 51 and 70 years (six patients, 38%), which is clearly shown in Figure 1 . If the adults only were counted, 85% of the patients with M0 were between 51 and 70 years. For comparison, the age of other non-M0 patients ranged from 1 month to 85 years (median, 37 years); 17 (4.1%) were less than 3 years and 88 (21%) were between 51 and 70 years. If the adults only were counted, 25% of the non-M0 patients were between 51 and 70 years. There was a higher incidence of organomegaly, such as lymphadenopathy or hepato-splenomegaly, in patients with AML-M0 than in other AML patients (M0 vs non-M0, 56.3% vs 29.2%; P = 0.025). Other clinical manifestations and routine laboratory data were similar between the two groups of patients (Table 3) .
Morphologic and cytochemical analysis
The morphologic pictures of leukemic blasts were heterogenous. In 12 cases, their blasts were like those of acute lymphoblastic leukemia (ALL) L1 or L2 subtype; in three cases, the blasts showed features of undifferentiated cells with large cell size, abundant basophilic cytoplasm, fine chromatin and inconspicuous nucleoli; monocytoid-shaped blasts were seen in one case. Some evidence of dyspoiesis, affecting any of the three cell lineages, was seen in 11 out of 13 evaluable patients (Table 2) . Azurophil granules or Auer rods were not seen in the blast cells in any case. Cytochemical stains including MPO, CAE, NBE and PAS were negative.
Immunophenotype and gene rearrangements
The results of surface marker analysis are listed in Table 1 . Panmyeloid markers CD13 and/or CD33 were expressed on leukemic cells in all 16 patients. CD7 and CD34 were expressed in 50% and 69.2% of these patients, respectively,
Figure 1
Comparisons of age distribution between M0 and non-M0 cases, shown as percentage of patients in each group. White bar indicates non-M0 group, and black bar for M0 group (P Ͻ 0.001). compared with 16.9% and 37.9%, respectively, in other non-M0 patients (P = 0.003 and 0.019, respectively). CD14, CD15, CD11b and HLA-DR were expressed in 6.3%, 18.7%, 37.5% and 68.8% of the patients, respectively. CD19 was expressed in one patient (1/16, 6.3%). Other lymphoid-associated antigens including CD2, CD5, CD10 and CD20 were all negative. CD41 and glycophorin-A were negative in the 13 and three patients studied, respectively. It was interesting that one patient (case 16) whose leukemic cells expressed CD19, CD33, CD14, CD15, CD11b and CD34 at diagnosis had M4 subtype of AML at relapse with disappearance of surface CD19 antigen at the same time. TCR␤ and lg gene rearrangement were checked on leukemic cells from 10 patients; all showed germline configuration including in the patient with CD19 expression.
Cytogenetic study
Cytogenetic study was performed on 12 patients, and 10 (83.3%) had clonal chromosomal abnormalities ( 
Treatment outcome
Treatment outcome of 16 AML-M0 patients is shown in Table  1 . Four patients, including two children (cases 3 and 4) and two adults (cases 11 and 13) did not receive chemotherapy because of their poor physical conditions. Three of the four patients died soon after diagnosis but the remaining one (case 13) lived for 50 months under strong supportive management. One patient (case 12), referred from another hospital, was lost to follow-up soon after diagnosis. Among the 11 patients who received conventional induction chemotherapy, five (45.5%), including four of seven (57.1%) children and one of four (25%) adults, achieved CR. The main cause of treatment failure was unresponsiveness to chemotherapy which was noted in five patients; the remaining one (case 1) died of sepsis at neutropenic stage. Two children remained in CR for more than 50 months whereas the adult and the remaining children relapsed at 11, 10 and 1 month, respectively. No second remission was obtained. None of our M0 cases received hematopoietic stem cell transplantation. With the exception of age, no other clinical or laboratory findings could be identified that differentiate patients with good outcome from those with poor prognosis. For comparison, adults with AML-M3 had a CR rate of 69.5%, a median overall survival time of 34.0 ± 7.4 months, a median event-free survival time of 15 ± 2.4 months and CCR duration of 30.0 ± 14.0 months. Other adult AML patients excluding those with M0 and M3 subtypes had a CR rate of 70%, a median overall survival time, eventfree survival and CCR duration of 15.0 ± 1.8, 9.0 ± 0.7 and 11.0 ± 1.4 months, respectively (Figure 2a and b) . In the pediatric group, only two patients were of AML-M3 and both were still alive without disease at the time of this report. The CR rate, duration of CR, overall survival time and event-free survival for childhood AML excluding M0 were 75%, 13.0 ± 2.6, 15.0 ± 2.0 and 11.0 ± 1.7 months, respectively. It was apparent that adults with AML-M0 had a significantly shorter overall survival time and event-free survival time (median, 2 months and 2 months, respectively) than those with M3 or other subtypes (P = 0.017 and P = 0.008, respectively; Figure 2a and b). The same was also true if M3 cases were removed from non-M0 cases. On the contrary, children with this subtype of AML did not show significantly worse prognosis than other pediatric AML (Figure 2c and 2d) .
Discussion
This is the first report that demonstrates the double peaks of age distribution in AML-M0: 3 years or younger (44%) and between 51 and 70 years (38%). Stasi et al 11 analyzed 15 adult patients with AML-M0; 11 of them were aged between 51 and 70 years. Eight of the 14 AML-M0 patients reported by Segeren et al 10 were between 51 and 70 years. No studies on pediatric patients have been reported yet. Hara et al 2 reported 11 children with acute undifferentiated leukemia. Five of them did not express lymphoid antigens on the cell surface and showed no lg or TCR gene rearrangements. These five patients might have AML-M0 though no complete analysis of myeloid antigen expression on the leukemic cells was performed. Four of the five patients were younger than 3 years. More studies are needed to confirm these findings. In this study, it was also found that the proportion of M0 subtype in childhood AML is higher than that in adult AML (8.2% vs 1.7%). The overall incidence of AML-M0 is similar to that in Western countries, which has been reported to be 0.1% to 9%. 3, 8, 10, 11, [16] [17] [18] [19] In this study, we confirmed that AML-M0 is a unique AML subtype, which showed higher incidence of organ infiltration and more frequent expression of CD7 and CD34, as well as complex cytogenetic changes of the leukemic cells than other AML subtypes. Although lg and TCR␤ gene rearrangements had been found in some AML-M0 cases, 8 all 10 patients tested in this study showed germline configuration of both genes, which was feasible to exclude lymphoid differentiation of the leukemic cells in these patients.
CD7 was expressed in 50% of the AML-M0 patients, an incidence significantly higher than that in other AML subtypes. Though CD7 is a T cell marker of high sensitivity and specificity, its coexpression on leukemic blasts has been demonstrated in approximately 15% of AML, especially in less differentiated subtypes. 20 CD7 expression in AML has been found to be associated with poor prognosis in some reports [21] [22] [23] [24] [25] but not others. 26, 27 Because the sample size is too small, it is impossible to clarify the prognostic implication of CD7 expression in this study. Interestingly, coexpression of CD19 with myeloid antigens on the leukemic cells was noted in one patient (case 16). CD19 was a B cell associated antigen, but could be found in some myeloid blasts in the absence of other features of lymphocytic leukemia. 21, 28 Because the blasts from this patient did not express other lymphoid markers and had neither lg or TCR␤ gene rearrangement, this patient was truly a case of AML-M0. Her leukemia turned to AML-M4 subtype at relapse 11 months later. Leukemic cells from several similar patients of AML-M0 reported by Venditti et al 18, 29 were also found to express frank M4/5 phenotypes after treatment. In that report, as high as 80% of the AML-M0 cases coexpressed lymphoid associated antigens on the leukemic cells; therefore, coexpression of lymphoid antigens on leukemic blasts should not rule out a diagnosis of AML-M0.
In this study, complex cytogenetic abnormalities were found more frequently in AML-M0 than in other subtypes, which might be implicated in the poor treatment response in this disease entity. Similar findings had been reported from other institutions. 8, 11, 18 There were no specific chromosomal abnormalities in this subtype of AML. The common aberrations shown in this study as well as from literature, such as +8, −7/7q−, −5/5q−, can also be detected in other hematologic malignancies.
Reports regarding treatment of AML-M0 are limited, and adequate therapy has not yet been defined. In general, conventional chemotherapy yields disappointing results, especially in adult patients, 6, 10, 11, 18, 30 which is also true in adults with AML-M0 in our study that the remission rate was low (25%) and the survival was short (median, 2 months). Though these patients received heterogenous regimen of chemotherapy, all but one (case 16) were treated with cytosine arabinoside and one of anthracyclines, at least, which were similar to the treatment for other subtypes of AML. Case 16 received ALL-directed chemotherapy initially who was the only one achieving CR. Case 14 was treated with a regimen directed to both AML and ALL, but failed to respond. However, the prognosis of AML-M0 in pediatric patients seemed not significantly worse than that of other AML. Four of seven (57.1%) children who received chemotherapy achieved CR and two (2/4, 50%) remained in remission after follow-up of more than 50 months. Reviewing the literature, a similar child with AML-M0 was also reported to have a long-term remission. 10 The unexpected fair prognosis in some childhood AML-M0 needs to be confirmed by further studies on more patients. The differences in the clinical and biological characteristics between patients responding well to chemotherapy and those not responding well warrant further scrutiny. One of the pediatric patients who had long disease-free survival was a case of Down syndrome. Recently, Lange et al 31 reported that AML in children with Down syndrome had more acute megakaryoblastic leukemia or undifferentiated AML and better survival than other patients. They did not mention specially the outcome of patients with undifferentiated AML in that report.
In summary, we found that AML-M0 had different age distribution from other AML which had not been reported before. AML-M0 occurred more frequently in childhood than in adult AML. Patients with AML-M0 had a higher incidence of organomegaly and a higher frequency of complex chromosomal abnormalities in the leukemic cells as well as CD7 and CD34 expression than those with other AML subtypes. Though the number of the patients studied was limited, adult patients with AML-M0 had a poorer prognosis than those with other AML subtypes, but pediatric patients showed no significant difference in survival between the two groups of patients. Two children with AML-M0 remained in CR for more than 50 months. Further studies on more patients are needed to find out, in addition to age, the clinical and biological differences which can differentiate patients with good response to chemotherapy from those not.
